Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema and cagrilintide for pediatric obesity
NL-OMON61080Phase 4Recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of CagriSema, cagrilintide, semaglutide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON61080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61080.